Bioassay-guided screening of antibacterial compounds from the cultured marine Streptomyces sp. ICN19 provided Alageninthiocin (1), along with its known analogs geninthiocin (2) and Val-geninthiocin (3) and the indolocarbazole staurosporine (4). The structure of 1 was determined on the basis of 1D and 2D NMR spectra and ESI-HRMS. The absolute configurations of the amino acid residues were determined by enantioselective GC-MS analysis. Compound 1 exhibited potent activity against Gram-positive bacteria including Staphylococcus aureus, Bacillus subtilis, Mycobacterium smegmatis, and Micrococcus luteus, as well as cytotoxicity against A549 human lung carcinoma cells with an IC 50 value of 6 nM.
The desirable biological activity of thiopeptides has stimulated renewed interest in the search for new antibiotics to find promising lead molecules. New groups of actinomycetes from unexplored habitats are pursued as sources of novel bioactive secondary metabolites. It is perhaps not surprising that marine Streptomyces are proving to be such a valuable source of new bioactive compounds [1] [2] [3] . As part of our continuing efforts to explore marine-derived actinomycetes, a new thiopeptide antibiotic was isolated from Streptomyces strain ICN19 derived from a marine sediment. The bioassay-guided chromatographic purification yielded a new compound named as Ala-geninthiocin (1) besides the known geninthiocin (2) , its analog Val-geninthiocin (3) and staurosporine (4) ( Figure. 1) . Details of the extraction, purification, structure elucidation, and biological activity are described herein.
Strong activity was found by bioassay screening against Staphylococcus aureus and Candida albicans in the acetone extract of Streptomyces sp. ICN19. After extracting the active metabolites with ethyl acetate and removing the lipids with n-heptane, the residue of the extract was fractionated using a reversed phased Medium-pressure liquid chromatography (MPLC) column with a methanol/water gradient. Of the 11 fractions collected, 3 fractions (fr. 4, 6, and 7) exhibited antibacterial activity, i.e., fr. 4 and 7 were active against S. aureus and fr. 6 was active against C. albicans. Fr. 4 was further purified using preparative RP-HPLC to give Ala-geninthiocin (1) along with geninthiocin (2) . The preparative HPLC of fr. 7 yielded Val-geninthiocin (3). The analytical HPLC profile of MPLC fr. 6 showed a single peak of staurosporine (4) . The compounds were separated as Val-geninthiocin with 7.62 min retention time (RT), Ala-geninthiocin with 8.34 min RT, geninthiocin with 9.02 min RT, and staurosporine with 21.38 min RT. The identification of the three purified metabolites was confirmed by comparing their NMR data with those reported in the literature [4] [5] [6] .
The molecular formula C 50 H 52 N 15 15 N HSQC spectrum showed 1 J NH couplings of amide protons and a terminal NH 2 group. The assignment of 1 H and 13 C NMR data is presented in Table 1 . Detailed analysis of the 1 H, 1 H COSY, and TOCSY NMR spectra of 1 identified spin systems belonging to proteinogenic amino acids Ala and Thr, which were confirmed from the long range correlations in the 1 H, 13 C HMBC spectrum. They were also compatible with the amino acid analysis of the hydrolysis products. The presence of 2 oxazoles and 1 thiazole was shown by characteristic 1 H and 13 C chemical shifts at δ H 8.71, 8.59, and 8.49 ppm (δ C 142.8, 140.1, and 126.9) in conjunction with the 1 H, 13 C HMBC correlations to adjacent quaternary carbons (see Fig. 2 ) a methyl signal at 2.62 and its long range correlations indicated the existence of a methyloxazole (Oxa-3) residue [4, 7] . The Z configuration of the methyl substituted double bond of Oxa-3 was established from an intraresidueal NOE between the methyl and NH protons. Furthermore, typical shifts, COSY and HMBC correlations identified the 2,3,6-trisubstituted pyridine residue that has Overlap of 1 H signals c Overlap of 13 C signals been found in other thiopeptides produced by Streptomyces [8, 9] .
Sequential assignments were determined from the cross peaks in the 1 H, 1 H ROESY spectrum by the NOE between H N , H α , H β in residue (i) to H N in residue (i + 1). In combination with HMBC correlations the sequential assignment method provided the complete amino acid sequence of 1 which showed that Pyr-9 was attached to Thz-1 to form a cyclic peptide. Finally the Deala-10 chain was found to be attached to Pyr-9 through long range correlations from H-6 of Pyr and NH of Deala-10 to the carbonyl carbon at 161.2 ppm. The peptide structure of 1 is largely similar to geninthiocin [4] . The only difference is the presence of an Ala residue instead of Deala at the C-terminal amide. The absolute stereochemistry of 1 was determined by enantioselective GC-MS analysis indicating the presence of L-Ala, L-Thr, and L-Hyval. Furthermore, the absolute configuration of Hyval residue from geninthiocin was assigned from the GC-MS analysis to be L as well, which can be also inferred for Val-geninthiocin as reported in the literature [5] .
Compounds 1-4 were evaluated for their antibiotic activities against a panel of human pathogenic bacteria, yeast, and fungi and all exhibited strong antibiotic activity as shown in Table 2 . Compounds 2, 3, and 4 were known to exhibit antimicrobial activity [5] , and compound 4 also acts as an anticancer agent targeting protein kinases [10] . Compound 1 showed inhibition of Staphylococcus aureus, Bacillus subtilis, Mycobacterium smegmatis, Micrococcus luteus, Chromobacterium violaceum, Candida albicans, Pichia anomala, and Mucor hiemalis. Compounds 1 and 2 inhibited C. violaceum but not compound 3. Similarly, compound 1 showed weak and compound 3 moderate activity against C. albicans while 2 was inactive. Thus, the antimicrobial activity of these analogs suggests that substitution of amino acids has little effect on their antimicrobial activity. [11] [12] [13] . Compound 1 showed potent antibacterial activity and weak antifungal activity. Comparatively, 3 showed better antifungal activity than its analogs. The antimicrobial activities of 2 and 3 described earlier [5] are correlating with our findings. Further, 2 has been reported as an inducer of the tip A promoter in streptomycetes [4] .
Furthermore, these compounds showed potent cytotoxic activity against the tested cervix, breast, lung, prostate, epidermoid, and ovarian human cancer cell lines. The IC 50 values of the analog compounds 1 and 3 were moderately higher than those of the basic compound 2 (Table 3) . However, compound 4 showed significantly higher cytotoxic activity. The anticancer activity of 4 is evidenced as broad spectrum protein kinase inhibitor with mitochondrial caspase activation [14, 15] . Cumulative research findings highlight the significant role of macrocyclic peptides in various cancer therapeutic modalities. Compound 1 showed cytotoxic IC 50 values of 22 nM against the mouse fibroblast cell line L929 and 6 nM against the human lung carcinoma cell line A549. Overall, 1 showed a higher selectivity towards mammalian cell lines than 2 in the cytotoxicity assays. It has been reported previously that the thiopeptide antibiotic thiostrepton is active against human breast cancer by inhibiting the FoxM1 transcription factor involved in tumorigenesis in the MCF7 cell line [16] , which is one of the possible modes of action of the thiopeptides described above.
In conclusion, along with the new thiopeptide Alageninthiocin (1), three bioactive compounds were isolated from the marine Streptomyces sp. ICN19. All have been assayed against a panel of human pathogenic bacteria, yeasts, and fungi for their antibiotic activity and against cervix, breast, lung, prostate, epidermoid, and ovarian human cancer cell lines and a murine fibrosarcoma cell line for anticancer activity. Macrocyclic peptides provide diverse functionality with high affinity and selectivity for target proteins, while maintaining adequate bioavailability for binding. The present findings indicate that the antibiotic and anticancer activity of the thiopeptides including the new thiopeptide Ala-geninthiocin (1), geninthiocin (2), and its analog Val-geninthiocin (3) may demand further preclinical evaluations for a future therapeutic use. The possible routes of their biosynthesis and preclinical safety are currently under investigation.
Materials and methods

General experimental procedures
Optical rotation was measured with a Perkin-Elmer 241 MC instrument, UV data recorded on a Shimadzu UV-Vis spectrophotometer UV-2450 using methanol (UVASOL, Merck). 1 H NMR, 13 C, and 15 N NMR spectra were recorded on a Bruker AVANCE DMX-700 ( 1 H 700 MHz, 13 C 176 MHz) spectrometer. ESI-HRMS mass spectra were obtained with a Maxis ESI-TOF mass spectrometer (Bruker Daltonics) attached to an Agilent 1200 series HPLC system: column 100 × 2.1 mm, C 18 XBridge TM, 3.5 µm (Waters), solvent A: 5% acetonitrile in water, 5 mmol L −1 NH4Ac, 0.04 ml L −1 acetic acid; solvent B: 95% acetonitrile in water, 5 mmol L -1 , 0.04 ml L −1 acetic acid, gradient 10% B increasing to 100% B in 30 min, and maintaining 100% B for 10 min, flow rate 0.3 ml min −1 ; UV detection 200-500 nm. Analytical RP-HPLC was carried out with an Agilent 1260 HPLC system equipped with a UV diodearray detector and a Corona Ultra detector (Dionex); column 125 × 2 mm, Nucleodur 5 µm C18 (Macherey Nagel), solvent A: 5% acetonitrile in water, 5 mmol L −1 NH 4 Ac, 0.04 ml L −1 acetic acid, solvent B: 95% acetonitrile, 5 mmol L −1 NH 4 Ac, 0.04 ml L −1 acetic acid, gradient from 10% B to 100% B in 30 min, 10 min 100% B, flow rate 0.3 ml min −1 . GC/MS analysis was performed on an automated Applied Biosystems ABI-420-A amino acid analyser.
Producer strain
The strain Streptomyces sp. ICN19 was isolated from subtidal marine sediment collected at two feet depth at Chinnamuttam coast of Kanyakumari, India, and isolated using standard dilution-plating with the modified Gause's inorganic agar media [17] containing 20 g soluble starch, 1 g KNO 3 , 0.5 g K 2 HPO 4 , 0.5 g MgSO 4 ·7H 2 O, 0.01 g FeS-O 4 ·7H 2 O, 18 g agar in 1 L of 50% sea water (pH 7.2-7.4). A pure culture was maintained in a glycerol suspension (20%, w/v) at −20°C. 16S rRNA gene sequencing was carried out and the aligned sequence was identified against closely 
Screening, extraction, and Isolation
GYM broth medium containing glucose 4 g, yeast extract 4 g, malt extract 10 g, CaCO 3 2 g, and distilled water 1 L adjusted at pH 7.2 using KOH was inoculated with a 1 cm 2 agar plug of a well sporulated mycelium from Streptomyces sp. ICN19 and incubated in a shaker at 30°C up to 7 days. After 7 days 5% by volume of this inoculum was transferred into 10 L shake flasks (100 × 250 ml flask with 100 ml broth) of medium HZI 5254 containing glucose 15 g, soymeal 15 g, corn steep 5 g, CaCO 3 2 g, NaCl 5 g, and distilled water 1 L at pH 7.0 and incubated in a shaker at 30°C up to 5 days. The production broth was harvested by centrifuging at 7000 rpm. Mycelial biomass and cell free supernatant were collected separately. The mycelial cake was extracted three times with acetone (900 ml). After filtration and evaporation, the residual water phase was partitioned with ethyl acetate six times and dried in vacuo. 
Biological assays
Antimicrobial assay: Minimum inhibitory concentrations (MIC) in µg ml −1 were determined in 96-well microtiter plates with EBS medium (0.5% peptone, 0.5% glucose, 0.1% meat extract, 0.1% yeast extract, 50 mM HEPES for bacteria, and MYC medium for yeast and fungi, respectively. Twenty microliter aliquots (150 µg ml −1 from 1 mg ml −1 concentration) of compounds were tested against four different Gram-positive (Staphylococcus aureus DSM 346, Bacillus subtilis DSM 10, Mycobacterium smegmatis DSM 43756, Micrococcus luteus DSM 1790) and three Gramnegative bacteria (Chromobacterium violaceum DSM 30191, Pseudomonas aeruginosa DSM 1128, Escherichia coli DSM 1116, Escherichia coli TolC), two yeasts (Candida albicans DSM 1386, Pichia anomala DSM 6766), and a fungal strain (Mucor hiemalis DSM 63298). Negative control wells were left blank. Compounds were dissolved in methanol. Cell density was adjusted to about 5 × 10 6 ml −1 .
Cytotoxicity assay: In vitro cytotoxicity (IC 50 ) was determined against seven cancer cell lines. A 60 μl amount of serial dilutions from an initial stock of 1 mg ml −1 in Methanol of the test compounds was added to 120 μl aliquots of a cell suspension (50,000 ml −1 ) in 96-well microplates. After 5 days of incubation, an MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed, and the absorbance measured at 590 nm using an ELISA plate reader (Victor). The concentration, at which the growth of cells was inhibited to 50% of the control (IC 50 ), was obtained from the doseresponse curves. The negative control was methanol.
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